Press Release
« Back
Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares
Feb 27, 2015
Celldex anticipates using the net proceeds from the offering to fund clinical trials of its product candidates, expansion of its pipeline, expansion of the commercial team and for working capital and other general corporate purposes.
A shelf registration statement relating to the shares was filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This announcement contains "forward-looking statements," including statements relating to Celldex's expectations regarding the completion and timing of the closing of the public offering and its anticipated use of net proceeds from the offering. These statements are subject to significant risks and uncertainties; actual results could differ materially from those projected and Celldex cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market and other conditions and the satisfaction of customary closing conditions related to the public offering. There can be no assurance that Celldex will be able to complete the public offering on the
anticipated terms, or at all. Risks and uncertainties relating to Celldex and its business can be found in the "Risk Factors" section of Celldex's Form 10-K, filed with the
CONTACT: Company Contact:Source:Sarah Cavanaugh Vice President of Investor Relations& Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 scavanaugh@celldex.com
News Provided by Acquire Media